Sanofi Consumer Healthcare India has posted impressive financial results for Q4’25, with a 50% jump in profit after tax (PAT) and a 47% rise in revenue. For the full year, the company achieved a 21% growth in revenue, delivering strong performance ac
Eli Lilly and Company (India) has launched the next phase of its obesity awareness campaign, using films led by well-known personalities to shift the focus from blame to science and encourage doctor-led care.
Lupin Limited has ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment, scoring 91 out of 100 and emerging as the top pharmaceutical company worldwide.
Alembic Pharma has received USFDA approval for its generic Lamotrigine Orally Disintegrating Tablets in multiple strengths, boosting its presence in the US generics market and expanding its epilepsy treatment portfolio.
Boehringer Ingelheim has received FDA approval for its drug Ofev as a first-line treatment for non-small cell lung cancer. The approval offers a new option for patients with metastatic NSCLC, combining Ofev with chemotherapy for better outcomes.
LTM has entered a seven-year, $100 million partnership with a leading European MedTech company specializing in hearing solutions, focusing on product development, digital support, and compliance management for hearing devices.
Mahajan Imaging & Labs reports an 85% rise in Calcium Scoring CT and 36% growth in advanced cardiac scans, highlighting early heart risk among young Indians and the need for preventive cardiology.
Novo Nordisk has signed a $2.1 billion deal with Vivtex to develop an oral obesity drug platform, aiming to turn injectable weight-loss treatments into easy-to-take pills and expand patient access worldwide.
Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection in India by March following patent expiry, aiming to offer a significantly lower-cost option for diabetes and weight-loss patients.
GSK plc will acquire Canada-based 35Pharma for $950 million, adding HS235, a phase I-ready drug candidate for pulmonary hypertension, to strengthen its growing cardiopulmonary pipeline.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")